Literature DB >> 1689753

HIV p24-specific helper T cell clones from immunized primates recognize highly conserved regions of HIV-1.

K H Mills1, P A Kitchin, B P Mahon, A L Barnard, S E Adams, S M Kingsman, A J Kingsman.   

Abstract

We have investigated Th cell recognition of the HIV core protein p24 by using CD4+ T cell clones derived from cynomolgus macaques immunized with hybrid HIV p24: Ty virus-like particles (VLP). T cell lines from two immunized animals responded to p24: Ty-VLP, control Ty-VLP, purified p24, and whole inactivated HIV, indicating the presence of T cells specific for p24 as well as the Ty carrier protein. The HIV determinants recognized by the T cell lines were identified by using a series of overlapping peptides synthesized according to the sequence of p24. Both T cell lines recognized peptide 11 (amino acids 235-249) and peptide 14 (amino acids 265-279). In addition, one T cell line also responded to peptide 9 (amino acids 215-229). Definitive identification of two T cell epitopes on p24 was confirmed at the clonal level: from a total of four T cell clones generated from one of the T cell lines, two respond specifically to peptide 11 and two to peptide 14. The T cell clones were CD4+ and MHC class II-restricted and secreted IL-2 in response to stimulation with purified p24, inactivated HIV or a single synthetic peptide. The specificity of the Th clones for variant peptides demonstrated cross-reactivity with two simian immunodeficiency virus isolates, but only limited responses to HIV-2 sequences. However, the Th cell epitopes identified on p24 are highly conserved between 12 HIV-1 isolates and were recognized by both of the immunized primates. These sequences may therefore be useful for priming a broadly reactive immune response to HIV-1.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689753

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion.

Authors:  J C Griffiths; S J Harris; G T Layton; E L Berrie; T J French; N R Burns; S E Adams; A J Kingsman
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

3.  Characterization of murine monoclonal antibodies directed against the core proteins of human immunodeficiency virus types 1 and 2.

Authors:  M Niedrig; J Hinkula; H P Harthus; M Bröker; L Hopp; G Pauli; B Wahren
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  Mucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunity.

Authors:  S Crotty; B L Lohman; F X Lü; S Tang; C J Miller; R Andino
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

5.  Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization.

Authors:  Sara Venturini; Donald E Mosier; Dennis R Burton; Pascal Poignard
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

6.  Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens.

Authors:  A D Kelleher; M Roggensack; S Emery; A Carr; M A French; D A Cooper
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

7.  Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.

Authors:  R Wagner; H Fliessbach; G Wanner; M Motz; M Niedrig; G Deby; A von Brunn; H Wolf
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

8.  Antigenic sequences of poliovirus recognized by T cells: serotype-specific epitopes on VP1 and VP3 and cross-reactive epitopes on VP4 defined by using CD4+ T-cell clones.

Authors:  B P Mahon; K Katrak; K H Mills
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant.

Authors:  J C Griffiths; E L Berrie; L N Holdsworth; J P Moore; S J Harris; J M Senior; S M Kingsman; A J Kingsman; S E Adams
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Enhanced proliferative cellular responses to HIV-1 V3 peptide and gp120 following immunization with V3:Ty virus-like particles.

Authors:  S J Harris; A J Gearing; G T Layton; S E Adams; A J Kingsman
Journal:  Immunology       Date:  1992-11       Impact factor: 7.397

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.